Latigo Biotherapeutics, Inc. (LTGO)
| Market Cap | 861.89M |
| Revenue (ttm) | n/a |
| Net Income | -107.29M |
| EPS | -10.41 |
| Shares Out | 66.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 267,166 |
| Open | 13.22 |
| Previous Close | 13.24 |
| Day's Range | 11.91 - 13.35 |
| 52-Week Range | 10.24 - 25.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 52.25 (+301.92%) |
| Earnings Date | Nov 5, 2026 |
About LTGO
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly k... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for LTGO stock is "Strong Buy." The 12-month stock price target is $52.25, which is an increase of 301.92% from the latest price.
News
Latigo Biotherapeutics Transcript: Jefferies Global Healthcare Conference
Commercial preparations are advancing alongside onzotrigine’s bunionectomy trial, with opioid-sparing evidence and faster onset central to its proposed differentiation. LTG-321’s chronic OA proof-of-concept readout is guided for H2 2027.
Latigo Biotherapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Onzotrigine’s bunionectomy study and the LTG-321 OA trial are both expected to read out in H2 2027. Cash of $401M is expected to fund operations into 2029.
Latigo Biotherapeutics, Inc. trading resumes
09:40 EST Latigo Biotherapeutics (LTGO), Inc. trading resumes
Latigo Biotherapeutics, Inc. trading halted, volatility trading pause
09:30 EST Latigo Biotherapeutics (LTGO), Inc. trading halted, volatility trading pause
Latigo Biotherapeutics, Inc. trading resumes
09:44 EST Latigo Biotherapeutics (LTGO), Inc. trading resumes
Latigo Biotherapeutics, Inc. trading halted, volatility trading pause
09:34 EST Latigo Biotherapeutics (LTGO), Inc. trading halted, volatility trading pause
Latigo Biotherapeutics says Todd Smith to succeed Nima Farzan as CEO
Latigo Biotherapeutics (LTGO) announced the appointment of Todd Smith as president and CEO, effective immediately. Smith, who has served as an independent director on Latigo’s board since July 2026, s...
Latigo Biotherapeutics Earnings release: Q3 2026
Latigo Biotherapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Latigo Biotherapeutics Quarterly report: Q3 2026
Latigo Biotherapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Latigo Biotherapeutics Slides: Corporate presentation
Latigo Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and co...
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medi...
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expe...
Latigo Biotherapeutics Earnings release: Q2 2026
Latigo Biotherapeutics released its Q2 2026 earnings on September 3, 2026, summarizing the period's financial results.
Latigo Biotherapeutics Quarterly report: Q2 2026
Latigo Biotherapeutics has published its Q2 2026 quarterly earnings report on September 3, 2026.
Latigo Biotherapeutics Slides: Corporate presentation
Latigo Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Latigo Biotherapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target The firm believes LTG-001 will show at least as good efficacy as Suzetrigine in its…
Latigo Biotherapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Latigo Biotherapeutics (LTGO) with an Outperform rating and $36 price target
Latigo Biotherapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target implying 127% upside. The company has two “binary catalysts and second-mover ...
Latigo Biotherapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology company developing non-opioid pain medicines without add...
Latigo Biotherapeutics opens at $21, IPO priced at $18 per share
Latigo Biotherapeutics (LTGO) – a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines – priced 19.2M shares at $18.00. The deal size was increased to ...
Latigo Biotherapeutics indicated to open at $20, IPO priced at $18
Latigo Biotherapeutics (LTGO) priced 19.2M shares at $18.00. The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end…
Latigo Biotherapeutics 19.2M share IPO priced at $18.00
The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end of the $16.00-$18.00 range. Goldman Sachs, Jefferies, Leerink…
Latigo Biotherapeutics Registration statement: Registration filing
Latigo Biotherapeutics filed a registration statement on August 4, 2026, providing details about a securities offering with the SEC.